Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more
Market Cap & Net Worth: Boule Diagnostics AB (publ) (BDABF)
Boule Diagnostics AB (publ) (PINK:BDABF) has a market capitalization of $304.45 Million ($304.45 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #14415 globally and #5801 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Boule Diagnostics AB (publ)'s stock price $7.84 by its total outstanding shares 38833100 (38.83 Million).
Boule Diagnostics AB (publ) Market Cap History: 2017 to 2024
Boule Diagnostics AB (publ)'s market capitalization history from 2017 to 2024. Data shows change from $1.32 Billion to $304.45 Million (-15.24% CAGR).
Boule Diagnostics AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Boule Diagnostics AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.53x
Boule Diagnostics AB (publ)'s market cap is 0.53 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
12.19x
Boule Diagnostics AB (publ)'s market cap is 12.19 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.32 Billion | $427.79 Million | $37.24 Million | 3.07x | 35.32x |
| 2018 | $263.23 Million | $424.40 Million | $41.03 Million | 0.62x | 6.42x |
| 2019 | $263.23 Million | $498.92 Million | $37.55 Million | 0.53x | 7.01x |
| 2020 | $263.23 Million | $400.46 Million | -$47.97 Million | 0.66x | N/A |
| 2021 | $283.09 Million | $463.34 Million | $23.27 Million | 0.61x | 12.16x |
| 2022 | $304.45 Million | $548.09 Million | $12.73 Million | 0.56x | 23.92x |
| 2023 | $304.45 Million | $571.33 Million | $24.98 Million | 0.53x | 12.19x |
Competitor Companies of BDABF by Market Capitalization
Companies near Boule Diagnostics AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Boule Diagnostics AB (publ) by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Boule Diagnostics AB (publ) Historical Marketcap From 2017 to 2024
Between 2017 and today, Boule Diagnostics AB (publ)'s market cap moved from $1.32 Billion to $ 304.45 Million, with a yearly change of -15.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $304.45 Million | 0.00% |
| 2023 | $304.45 Million | 0.00% |
| 2022 | $304.45 Million | +7.54% |
| 2021 | $283.09 Million | +7.54% |
| 2020 | $263.23 Million | 0.00% |
| 2019 | $263.23 Million | 0.00% |
| 2018 | $263.23 Million | -79.99% |
| 2017 | $1.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 10th, 2025 the market cap of Boule Diagnostics AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $304.45 Million USD |
| MoneyControl | $304.45 Million USD |
| MarketWatch | $304.45 Million USD |
| marketcap.company | $304.45 Million USD |
| Reuters | $304.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.